CDKN2A and cancer: Because p16Ink4a-KO mice die of cancer long before they reach the age at which most normal mice experience a decline in SMG function, it is difficult to know whether dysregulation of the Bmi-1/p16Ink4a pathway is responsible for the aging-associated decline of SMG function.